Literature DB >> 1293049

Cerebrospinal fluid neopterin and beta 2-microglobulin levels in neurologically asymptomatic HIV-infected patients before and after initiation of zidovudine treatment.

L Hagberg1, G Norkrans, M Andersson, H Wachter, D Fuchs.   

Abstract

The effect of zidovudine on beta 2-microglobulin and neopterin in the cerebrospinal fluid (CSF) was studied in ten HIV-seropositive neurologically healthy individuals. CSF concentrations of neopterin decreased by 53% (from 20.3 to 9.5 nmol/l, p < 0.01) and beta 2-microglobulin by 36% (from 2.8 to 1.8 mg/l, p < 0.01) four to eight months after initiation of therapy.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1293049     DOI： 10.1007/bf01710672

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  13 in total

1.  The AIDS dementia complex: I. Clinical features.

Authors:  B A Navia; B D Jordan; R W Price
Journal:  Ann Neurol       Date:  1986-06       Impact factor: 10.422

2.  Isoelectric focusing followed by silver staining. A suitable method for routine investigation of cerebrospinal fluid proteins.

Authors:  C Wikkelsö; M Andersson; R Andersson; C Blomstrand
Journal:  Eur Neurol       Date:  1984       Impact factor: 1.710

3.  Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection.

Authors:  D Fuchs; T J Spira; A Hausen; G Reibnegger; E R Werner; G W Felmayer; H Wachter
Journal:  Clin Chem       Date:  1989-08       Impact factor: 8.327

4.  Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1.

Authors:  D Fuchs; F Chiodi; J Albert; B Asjö; L Hagberg; A Hausen; G Norkrans; G Reibnegger; E R Werner; H Wachter
Journal:  AIDS       Date:  1989-05       Impact factor: 4.177

5.  Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment.

Authors:  B J Brew; R B Bhalla; M Paul; J J Sidtis; J J Keilp; A E Sadler; H Gallardo; J C McArthur; M K Schwartz; R W Price
Journal:  AIDS       Date:  1992-05       Impact factor: 4.177

6.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

7.  Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.

Authors:  P Portegies; J de Gans; J M Lange; M M Derix; H Speelman; M Bakker; S A Danner; J Goudsmit
Journal:  BMJ       Date:  1989-09-30

8.  Measurement of beta-2-microglobulin in serum and plasma by an enzyme-linked immunosorbent assay (ELISA).

Authors:  O W Bjerrum; H S Birgens
Journal:  Clin Chim Acta       Date:  1986-02-28       Impact factor: 3.786

9.  Elevated serum beta-2-microglobulin--a prognostic marker for development of AIDS among patients with persistent generalized lymphadenopathy.

Authors:  J Morfeldt-Månson; I Julander; L V von Stedingk; J Wasserman; B Nilsson
Journal:  Infection       Date:  1988 Mar-Apr       Impact factor: 3.553

10.  Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort.

Authors:  A R Moss; P Bacchetti; D Osmond; W Krampf; R E Chaisson; D Stites; J Wilber; J P Allain; J Carlson
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-12
View more
  1 in total

Review 1.  Compartmentalized intrathecal immunoglobulin synthesis during HIV infection - a model of chronic CNS inflammation?

Authors:  Mickael Bonnan; Bruno Barroso; Stéphanie Demasles; Elsa Krim; Raluca Marasescu; Marie Miquel
Journal:  J Neuroimmunol       Date:  2015-05-16       Impact factor: 3.478
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.